Joe Y Chang, Professor and Clinical Section Chief at MD Anderson Cancer Center, shared on X:
“I am pleased to share the results of our phase II randomized I-SABR study ASTRO 2026 which demonstrate improved overall survival (OS) when adding four doses of immunotherapy to SABR in early-stage NSCLC.
These exciting findings are associated with the persistent activation of cytotoxic T cells for up to 6.5 years.
Further optimization of I-SABR approaches will guide future research and clinical practice.”
Other articles about ASTRO 2026 on OncoDaily.